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OBJECTIVE—To estimate the accuracy of Neuropad for the diagnosis and staging of distal
symmetric polyneuropathy (DPN) across different stages of neuropathy, using multiple-level
likelihood ratios (LRs) to interpret the time necessary to complete the color change of the test.
RESEARCH DESIGN AND METHODS—We conducted a cross-sectional, cohort-type
diagnostic accuracy study in 251 consecutive adult type 2 diabetic patients with no peripheral
arterial disease or other potential causes of neuropathy, who were recruited between January
2005 and December 2008 from the diabetes outpatient clinics in Alexandroupolis Hospital,
Greece. Patients were tested for DPN by means of the neuropathy disability score (NDS) and
Neuropad. Multiple-level LRs for time to complete color change were calculated across different
stages of neuropathy.
RESULTS—The areas under the curve for the diagnosis of any (NDS of $3), at least moderate
(NDS of $6), or severe (NDS of $9) DPN were 0.91, 0.96, and 0.97, respectively. The calcu-
lation of multiple-level LRs showed that time to complete color change ,360 s suggested the
absence of neuropathy. Values between 360 and 1,000 s were indicative of mild neuropathy.
Finally, values between 1,000 and 1,200 or .1,200 s were strongly suggestive of moderate or
severe DPN, respectively.
CONCLUSIONS—Neuropad could be used as a triage test for the diagnosis and staging of
DPN in patients with type 2 diabetes, prompting referral to specialized care setting.
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D
istal symmetric polyneuropathy
(DPN) is a major debilitating com-
plication of diabetes (1). DPN is as-
sociated with a signiﬁcant increase in
morbidity and represents a cardinal etio-
logic factor for the development of dia-
betic foot lesions (1–3). Diagnosis of
DPN is based on clinical examination to
identify neurologic deﬁcits. Clinical prac-
tice recommendations of the American
Diabetes Association suggest annual
screening of patients with diabetes for
DPN and advocate diagnosis by means of
simple clinical tests, such as the pin-prick
sensation, vibration perception (using a
128-Hz tuning fork), or 10-g monoﬁla-
ment pressure sensation (1,4).
Neuropad (Trigocare International,
Wiehl, Drabenderhöhe, Germany) is a
new diagnostic test with high sensitivity
forthe diagnosisofDPN(5–9).Itisasim-
ple adhesive indicator test that has been
found to be suitable for patient self-
examination at home (10). Although
this holds true for Neuropad interpreted
for screening purposes as normal or ab-
normal after 10 min of application on the
plantaraspectofthefeet,thereisevidence
that prolonging the time of observation
after application might be useful in in-
creasing the sensitivity for neuropathy
and in providing a reliable clue to the se-
verity of neuropathy (6,8). Hence, one
might attempt to deﬁne multiple-level
likelihood ratios (LRs) for Neuropad to
increaseitsdiagnosticutilityandfacilitate
prompt specialist referral, where appro-
priate. The aim of the current study was
to examine the accuracy of Neuropad for
the diagnosis and staging of DPN across
different stages of neuropathy, using
multiple-levelLRstointerpretthetimenec-
essary to complete the color change of the
test.
RESEARCH DESIGN AND
METHODS—We conducted a cross-
sectional, cohort-type diagnostic accu-
racy study in adult subjects with type 2
diabetes, who were consecutively re-
cruited from the Outpatient Clinic of
Obesity, Diabetes, and Metabolism in
the Second Department of Internal Med-
icine, Democritus University of Thrace,
Greece, and the Diabetes Clinic, Univer-
sity Hospital of Alexandroupolis, Greece,
between January 2005 and December
2008. Individuals meeting any of the
following criteria were excluded: age
,17or.75years,peripheralarterialdis-
ease (deﬁned as ankle-brachial index
,0.9 in at least one foot, as measured
by a Doppler apparatus), other potential
causes of neuropathy, thyroid disease,
drugs that may affect perspiration, and
skin diseases (neurodermatitis, psoriasis,
scleroderma, allergy to metals, Raynaud
syndrome, hyperhidrosia, or acrocyano-
sis). The study was conducted and re-
ported in accord with the Standards for
the Reporting of Diagnostic Accuracy
Studies (STARD) principles (11). The
study protocol was approved by an insti-
tutional review board, and informed con-
sent was obtained from all subjects.
Characteristics of patients
A total of 340 potentially eligible consec-
utive adult subjects with type 2 diabetes
were identiﬁed and informed about the
study. Of these, 251 consented to take
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ORIGINAL ARTICLEpart in the study. Thirty-nine patients
were excluded because of exclusion cri-
teria: 30 patients because of peripheral
arterial disease, 5 patients because of
other causes of neuropathy, and 4 pa-
tients because of skin diseases. Finally,
212 patients were included in the study
and the analysis (Supplementary Fig. 1).
Patient demographics and major clinical
characteristics are listed in Table 1. Mean
age 6 SD of patients was 62 6 8y e a r s ,
and 107 (50.5%) patients were men,
with a mean duration of diabetes of
11 6 4 years. All patients underwent
both the reference test (neuropathy dis-
ability score [NDS]) and Neuropad.
Both tests were applied within 2 weeks.
NDS
Distal symmetric polyneuropathy (DPN)
was diagnosed through the NDS. The
NDS is a standardized examination of
ankle reﬂexes, as well as 128-Hz tuning-
fork, pin-prick, and temperature sensa-
tion at the hallux (12). It is very reliable,
because it encompasses the examination
of several modalities and enables a global
assessment of neuropathy inasmuch as it
permits examination of both large-ﬁber
(ankle reﬂexes and vibration perception)
and small-ﬁber (pin-prick and tempera-
ture sensation) function (12). This con-
trasts with other diagnostic tests, such as
nerve conduction study and skin biopsy,
whichonlyexaminelarge-andsmall-ﬁber
function, respectively (13,14). Of addi-
tional signiﬁcance, NDS has been docu-
mented as a reliable strong predictor of
the future risk for foot ulceration (1,15).
However, the NDS can only be imple-
mented by trained health care profes-
sionals and could be criticized for having
considerable interobserver disagreement,
just like its constituting parts (16).
Based on the NDS score, patients
were grouped as having no neuropathy
(NDS of 0–2), mild neuropathy (NDS
of 3–5), moderate neuropathy (NDS of
6–8), and severe neuropathy (NDS of
9–10) (12,17). The reference test (NDS)
was performed by N.P., who was blinded
to Neuropad results but might have been
aware of patient history and previous
HbA1c results.
Neuropad
ExaminationwithNeuropadwasperformed
aspreviouslydescribed(18).Patientswere
allowed a 10-min acclimatization period
inconstantroomtemperature(25°C)after
they had removed their socks and shoes.
Indicator tests were applied to both soles
at the level of the ﬁrst through second
metatarsalheads.Thetimetocolorchange
was deﬁned as the time in seconds that
was required until a complete color
change of the indicator test from blue
into uniform smooth pink and was re-
corded with exactitude of 10 s. For each
patient, we observed the time to color
change in each foot and recorded the lon-
ger of these two values as more represen-
tative of neuropathy status. Examination
with Neuropad was carried out by either
one of two physicians (D.P. or K.Pap.),
blindedtoneuropathystatus(resultofref-
erence test), patient history, and HbA1c
results.
Multiple-level LR cutoff points
The choice of multiple-level LR cutoff
points is often based on arbitrary criteria.
This can be avoided by a priori deﬁnition
of selection criteria. At the beginning of
the study, we decided that we would
choose cutoff points based on values
deriving from data analysis (receiver
operating characteristic [ROC] curves).
These would be rounded to numbers that
could represent intuitive boundaries. We
also decided that we would use the exist-
ing cutoff value of 600 s, in order to link
our ﬁndings with standard clinical prac-
tice and make them more clinically rele-
vant (19).
Statistical analysis
Statistical tests were performed using
SPSS version 17.0. All values were ex-
pressed as means 6 SD. Normality was
evaluated with the Kolmogorov-Smirnov
or the Shapiro-Wilk test, as appropriate.
The Mann-Whitney test was used for
comparison between two groups, and
the Kruskal-Wallis test was used to com-
pare more than two groups. Post hoc mul-
tigroupcomparisonanalysiswasconducted
with the Bonferroni test. The x
2 test was
used for categoricalvariables.Atwo-tailed
P value of , 0.05 was considered statisti-
cally signiﬁcant. ROC curves were con-
structed to assess the overall accuracy of
Neuropad and to identify optimal cutoffs.
The optimal cutoffs of Neuropad were
chosenatpointswiththehighestYouden’s
index (19). Multiple-level LRs were used
to explore the relationship between the
time to complete color change of the test
and neuropathy status. The advantage of
this approach is that computation of LRs
(unlikesensitivity,speciﬁcity,andpositive
and negative predictive values) does not
require dichotomization of test results,
whichmaydiscardusefuldiagnosticinfor-
mation. Furthermore, knowledge of the
LR of a particular test result enables the
calculation of posttest probability for a
given patient, using a simple nomogram
and the pretest probability (20). CIs of
90% were calculated using CIA software
(version2.1.2;TrevorBryant,Southampton,
U.K.).LRs.10and,0.1areconsideredto
provide strong evidence to rule in or rule
out diagnoses, respectively (20).
RESULTS—According to the NDS, 4
patients(2%) hadnoneuropathy(NDSof
0–2), 108 patients (51%) had mild
Table 1—Characteristics of study participants
NDS
No neuropathy
(0–2)
Mild neuropathy
(3–5)
Moderate neuropathy
(6–8)
Severe neuropathy
(9–10) P (Kruskal-Wallis)
Sex (male/female) 3/1 50/58 33/22 21/24 0.26*
Age (years) 55.2 6 6.6† 60.2 6 8.6† 62.2 6 6.4† 68.3 6 4.9 ,0.001
Diabetes duration (years) 6.0 6 3.3†‡ 9.4 6 2.8†‡ 12.9 6 2.3† 16.3 6 4.3 ,0.001
HbA1c 7.3 6 0.3 7.1 6 0.5 7.1 6 0.5 7.3 6 0.6 NS
Neuropad time to color
change (s) 402 6 106†‡ 576 6 197†‡ 1,090 6 295† 1,736 6 340 ,0.001
Data are means 6 SD. *x
2. †P , 0.008 vs. NDS = 9–10. ‡P , 0.008 vs. NDS = 6–8. A Bonferroni correction was applied and results are reported at a 0.008 level of
signiﬁcance.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JUNE 2011 1379
Papanas and Associatesneuropathy (NDS of 3–5), 55 patients
(26%) had moderate neuropathy (NDS
of6–8),and 45 patients(21%) had severe
neuropathy (NDS of 9–10). There was a
signiﬁcant difference in age, diabetes du-
ration,and time to completecolor change
across groups at different stages of neu-
ropathy (P , 0.001) but no such differ-
ence in HbA1c.
The diagnostic performance of Neu-
ropad across different stages of neuropa-
thy was assessed by means of the area
under the ROC curve. The area under the
ROC curve for diagnosis of any distal
symmetric polyneuropathy (NDS of $3)
was 0.91 (90% CI 0.76–1.00). The data-
driven optimal cutoff was 365 s, with a
sensitivity of 95% (92–97), speciﬁcity of
75% (36–94), positive predictive value of
99% (98–100), and negative predictive
value of 21% (9–43). The area under the
ROC curve for the diagnosis of moderate
or severe distal symmetric polyneurop-
athy (NDS of $6) was 0.96 (0.74–0.98).
The optimal cutoff was 1,005 s, with a
sensitivity of 91% (85–95), speciﬁcity of
96% (92–98), positive predictive value of
96% (91–98), and negative predictive
value of 92% (87–95). The area under
the ROC curve for the diagnosis of severe
distalsymmetricpolyneuropathy(NDSof
$9) was 0.97 (0.95–0.99). The optimal
cutoff was 1,190 s, with a sensitivity of
91% (82–96), speciﬁcity of 95% (92–
97), positive predictive value of 84%
(73–91), and negative predictive value
of 98% (95–99) (Table 2).
Multiple-level LRs
The choice of cutoff points was based on
predeﬁned criteria. The optimal cutoff
points that were calculated from ROC
curves for diagnosis of mild, moderate,
and severe DPN were 365, 1,005, and
1,190 s, respectively (Fig. 1). These num-
berswereroundedtotheclosestonesthat
could represent an intuitive boundary, in
order to facilitate implementation in ev-
erydayclinicalpractice.Hence,wedecided
touse 360, 1,000, and 1,200 s,adding as a
ﬁnalcutpoint600s,whichalreadyiswidely
used.
Timetocompletecolorchange.600s
practically suggested the presence of
some kind of neuropathy: the LR for ab-
senceofneuropathy(NDSof0–2)fortime
to complete color change equal to 600–
1,000, 1,001–1,200 or .1,200 is 0.0
(90% CI 0.00–2.39), 0.0 (0.00–2.23),
and 0.0 (0.00–2.19), respectively (Table
3). Indeed, a value between 600 and
1,000wasassociatedwithincreasedprob-
ability for mild neuropathy (NDS of 3–5)
(7.51 [3.23–18.00]). Time to complete
color change between 1,000 and 1,200
was indicative of moderate neuropathy
(NDS of 6–8) (12.05 [6.37–23.17]), and
values .1,200 s were strongly suggestive
of severe neuropathy (NDS of 9–10)
(18.44 [9.55–36.35]).
On the contrary, time to complete
color change between 360 and 600 s
suggested the absence of moderate or
severe neuropathy (0.21 [90% CI 0.08–
0.51] and 0.00 [0.00–0.22], respectively)
and was indicative of mild neuropathy
(10.40 [4.54–24.58]). Finally, values
,360 s suggested the absence of moder-
ate or severe neuropathy (0.00 [0.00–
0.74] and 0.00 [0.00–0.95], respectively)
and were suggestive of the absence of any
neuropathy (14.18 [4.98–28.12]).
CONCLUSIONS—Neuropad is a new
test that already has been shown to yield
high sensitivity for the diagnosis of DPN
(5–9). The current study is the ﬁrst to de-
ﬁnemultiple-level LRsforNeuropad time
to complete color change. These now
emerge as useful for the detection and
staging of DPN. Indeed, we found that
any value .600 s excludes all patients
withoutanyneuropathy.Speciﬁcally,val-
ues between 600 and 1,000, 1,000 and
1,200,and.1,200sarehighlysuggestive
for mild, moderate, and severe neuropa-
thy, respectively. By contrast, time to
complete color change ,1,000 s practi-
cally excludes the possibility of severe
clinical neuropathy. Values between 360
and 600 and ,360 s are strongly indic-
ative of mild neuropathy and no neu-
ropathy, respectively. Our results verify
previous reports suggesting that the
dichotomous interpretation of Neuropad
(i.e., normal or abnormal at 10 min)
discards valuable information (6,8).
Conversely, the study of different time
thresholds, as shown in this and in pre-
vious studies (6,8), although more time
consuming,providesadditionalinforma-
tiononthestagedseverityofDPN.Taken
together, these ﬁndings argue for a more
detailedinterpretationofNeuropadtoin-
crease diagnostic information obtained.
Thecurrentstudyhasseveralstrengths.
The sample represents a large group of
consecutive type 2 diabetic patients. An-
other strength of the study is the meth-
odology: both the indicator and the
reference tests were undertaken in all
patients, the indicator test was interpreted
by two physicians unaware of the results
of the reference test or of patients’ history
and glycemic control, and the results are
reported according to STARD principles.
A ﬁnal strength is the practical utility of
deﬁning new cutoff values for Neuropad.
Use of the latter enhances the diagnostic
utility of Neuropad for the diagnosis and
staging of DPN and might enable appro-
priate specialist referral. Therefore, we be-
lieve that Neuropad is powerful in the
diagnosis and staging of DPN in patients
with type 2 diabetes when used in a non-
dichotomous approach (by means of
multiple-level LRs).
A limitation of this study is the ab-
sence of comparison with an alternative
diagnostic test, but this was beyond the
scope of the present work. An additional
limitation is that very few patients had no
neuropathy (NDS of 0–2). Complete ab-
sence of neuropathic signs was less com-
mon in our study than in previous works
(17,21). The implication of the very low
frequency of no neuropathy could be that
the Neuropad cutoff value computed for
this category might be less reliable and of
diminished external validity for a differ-
ent population. However, the frequency
of no neuropathy and mild neuropathy
(i.e., NDS of ,6) in the current study
was similar to the two previous works.
Altogether,it isthis threshold of clinically
signiﬁcant neuropathy (NDS of $6) that
Table 2—Accuracy of Neuropad (90% CI)
Cutoff (s) Sensitivity (%) Speciﬁcity (%)
Positive predictive
value (%)
Negative predictive
value (%) +LR 2LR
NDS of $3 365 95 (92–97) 75 (36–94) 99 (98–100) 21 (9–43) 3.79 (0.91–15.82) 0.07 (0.04–0.14)
NDS of $6 1,005 91 (85–95) 96 (92–98) 96 (91–98) 92 (87–95) 25.48 (11.31–57.38) 0.09 (0.06–0.16)
NDS of $9 1,190 91 (82–96) 95 (92–97) 84 (73–91) 98 (95–99) 19.02 (10.71–33.78) 0.09 (0.04–0.21)
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Diagnostic accuracy study of Neuropadidentiﬁes patients at risk for foot ulcera-
tion (15). In accordance, the high LR
shown for the 1,000-s threshold to detect
clinically signiﬁcant neuropathy under-
lines the importance of this interpretative
approach.
It is important to note that Neuropad
does not require involvement of trained
health care professionals and is easy to
carryout.Therefore,itcouldbeusedboth
bypatientsandtheirphysiciansasatriage
test to diagnose clinically relevant neu-
ropathy and prompt referral to special-
ized care if necessary (22). Moreover,
compared with tests proposed in current
clinical practice recommendations for
general use (4), Neuropad has the incre-
mental advantage of providing some
additional information on autonomic
neuropathy, as shown by previous studies
(7,8). Not to be underestimated, patients
with diabetes also may exhibit autonomic
neuropathy, which is associated with in-
creased mortality, as recently reafﬁrmed
(23). Thus, Neuropad could be used as
an add-on diagnostic test. Finally, Neuro-
pad provides readily visible results, which
are comprehensible for the patients them-
selves. For this reason, it arouses patients’
interest in foot care and may be used to
promote patient education on diabetic
foot complications (5).
Thepracticalimplicationsofthepres-
ent work could be outlined as follows. In
patients with type 2 diabetes, time until
complete color change of Neuropad
could be measured during their usual
medical care. On the basis of this mea-
surement, patients who test negative on
the triage test (,360 s) have no DPN or
mildDPN,donotneedtobeexaminedby
the reference test, and require no special
medical attention other than general
measures of optimal glycemic control,
regular foot examination, and education
on foot hygiene (4,24,25). At this level,
given the reported excellent correlation
in Neuropad reading (blue or pink) be-
tween physician use and patient self-
examination at home (10), it is plausible
that Neuropad could be used by the pa-
tient himself or herself to rule out any
neuropathy. If time to complete color
change is not ,360 s, the patient should
be encouraged to visit a specialist and
seek appropriate medical care. Patients
with time to color change between 360
and 600 s probably have mild DPN and
should be reassessed in a follow-up visit.
Likewise, patients with values between
600 and 1,000 s could have mild or mod-
erate DPN and thus need reevaluation
with the reference test and monitoring
by their treating physicians. Patients
with time to color change between
1,000 and 1,200 s have moderate DPN
and need more thorough medical atten-
tion. They should be referred to a diabe-
tologist and/or podiatrist for initial
specialist assessment to determine the
necessaryfrequencyoffollow-up.Finally,
patients scoring .1,200 s appear to have
severe DPN and should be promptly
referred to the specialized foot care team
for evaluation and arrangement of close
Table 3—Multiple-level LRs (90% CIs) across different stages of neuropathy
Time to complete
color change (s)
NDS
0–23 –56 –89 –10
0–360 14.18 (4.98–28.12) 3.46 (1.08–11.33) 0.00 (0.00–0.74) 0.00 (0.00–0.95)
361–600 0.90 (0.16–2.63) 10.40 (4.54–24.58) 0.21 (0.08–0.51) 0.00 (0.00–0.22)
601–1,000 0.00 (0.00–2.39) 7.51 (3.23–18.00) 0.37 (0.15–0.83) 0.00 (0.00–0.30)
1,001–1,200 0.00 (0.00–2.23) 0.09 (0.03–0.23) 12.05 (6.37–23.17) 0.44 (0.19–0.98)
.1,200 0.00 (0.00–2.19) 0.00 (0.00–0.07) 0.57 (0.28–1.09) 18.44 (9.55–36.35)
Figure 1—ROC curves for the diagnosis of any DPN (NDS of $3) (A),at least moderate DPN (NDS of$6) (B), and severe DPN with Neuropad in
thestudypopulation(C).Thestraightlinerepresentsdiagnosisbasedonchancealone(areaunderthecurve0.50).TheareasundertheROCcurves
are as follows: 0.91 (90% CI 0.76–1.00) (A), 0.96 (0.76–0.98) (B), and 0.97 (0.95–0.99) (C).(A high-quality color representation ofthis ﬁgure is
available in the online issue.)
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Papanas and Associatesspecialist follow-up (4,24,25). In this
simple manner, the indicator test may
help toward timely and appropriate iden-
tiﬁcation of high-risk patients.
In conclusion, our results favor the
use of Neuropad as a triage test to help
toward timely and appropriate identiﬁca-
tion of high-risk patients. Time to com-
plete color change and multiple-level LRs
are of substantial help in the detection
andstagingofDPNindiabetes.Theutility
of Neuropad for follow-up of patients
with DPN and the optimal frequency that
this test should be used remain to be
shown. Finally, prospective studies are
needed to prove if the results obtained by
Neuropad testing predict hard outcomes
(mainly foot ulcers).
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